Mezzion Pharma announced a milestone in its clinical development program, having secured approximately $20 million in strategic funding to support the ongoing global Phase 3 FUEL-2 trial of udenafil for patients with Fontan circulation. The funding was led by Midas-Meritz New Technology Finance Association and KDBC-Korea Investment & Securities New Technology Investment Association, representing a decisive vote of confidence from top-tier institutional investors in Mezzion’s late-stage pipeline and long-term growth strategy.
This funding follows growing clinical and regulatory momentum for Mezzion. And the introduction of dedicated ICD-10 codes for Fontan-associated conditions marks a significant step forward in recognizing and addressing the needs of this long-overlooked population. It enhances care, improves coverage, and underscores Mezzion’s leadership and long-term commitment to advancing treatment for rare congenital heart disease.
KEY QUOTES:
“We are pleased to partner with Midas Private Equity (Midas PE) and KDBC as we enter a critical phase in the development of udenafil for the Fontan population, a community with significant unmet medical need. This investment affirms the strength of our data, the quality of our science, and the potential impact of our work on patients worldwide.”
“With accelerating enrollment and growing engagement across clinical sites, we believe time and data are now working in our favor. We have initially secured $20 million, and we will continue our efforts to receive valuable investments in the future.”
Dean Park, Chairman and CEO of Mezzion
“After a detailed review of Mezzion’s FUEL-1 results and the ongoing FUEL-2 protocol, we believe udenafil is well positioned for successful global Phase 3 completion and regulatory approval. We are proud to support Mezzion as it expands internationally and continues its leadership in rare disease innovation.”
Midas PE CEO Lim Chun-soo
